Retinitis Pigmentosa patients treated with ozone therapy during 20 years. Cuban experiences
Retinitis Pigmentosa (RP) is characterized by bad night vision, decrease of visual field and/or acuity, with electroretinogram (ERG) diminished in amplitude and finally, non reproducible. Taking into account some of the ozone biological effects, as: improvement in the oxygen metabolism, increase in...
Saved in:
Published in | Revista Española de Ozonoterapia Vol. 1; no. 1; pp. 13 - 22 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Asociación Española de Profesionales Médicos en Ozonoterapia (AEPROMO)
2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Retinitis Pigmentosa (RP) is characterized by bad night vision, decrease of visual field
and/or acuity, with electroretinogram (ERG) diminished in amplitude and finally, non
reproducible. Taking into account some of the ozone biological effects, as: improvement
in the oxygen metabolism, increase in the cell energy, the immunomodulator capacity
and enhancement of the antioxidant defense system the aim of this paper is to assess
ozone therapy s efficacy i n these patients, treated twice a yea r during 20 years . A
cont r olled and retrospect i ve clin i cal s tudy was performed in 56 patients with Typical
Retinitis Pigme ntosa (non-associa ted) , with sample homogeneity, in age, sex and
stage of the disease, and with signed informed consent. Forty patients received ozone
daily, by rectal way, during 20 sessions (at a concentration of 40 mg/L and a volume
of 200 mL) as only treatment, w i th repe tition of this cy cle every 6 m onths, a nd 16
rec e i ved other medical treatmen ts (control group). Resul ts showed that , after 10
years, patients in stages I and II h ad a better r esp onse to ozone therap y, a nd th i s
response was more la sting, with an improvement attained as of 4 months, which is
the shortest time period for patients in stages II and IV. After 20 years of treatment,
50.1 % of patients improved their visual field, 31.1 % remained the same and 18 %
followed the course of the disease. In respect to visual acuity, we observed that 37.5%
of patients improved, 34.9 % remained stable and 27.6 % continued the course of the
disease. It is recommended to apply ozone therapy at six-month intervals in order to
delay the course of the disease and maintain the visual capabilities. No side effects
were observed. Ozone therapy is a good therapeutic choice in the treatment of patients
with RP increasing their quality of life. |
---|---|
ISSN: | 2174-3215 |